Drug intelligence / Profile preview

elymus repens pollen

Development stage
Unknown
Lead developer
ALK Abelló
Modality
Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
Administration
Percutaneous, Intradermal, Subcutaneous
01

Overview

Elymus repens pollen is a non-standardized allergenic extract derived from the pollen of Elymus repens, commonly known as couch grass or quack grass. Developed and manufactured by ALK-Abello, it is a biologic product used for both the diagnosis and treatment of allergies specific to this pollen. For diagnosis, it is administered via percutaneous (prick) or intradermal skin tests to identify sensitization. As a therapeutic agent, it is used in allergen-specific immunotherapy, typically administered through subcutaneous injections. The treatment works by gradually exposing the patient's immune system to the allergen, which induces immune tolerance, reduces the production of IgE antibodies, and promotes a shift towards a non-allergic immune response, thereby mitigating symptoms of allergic rhinitis and conjunctivitis upon natural exposure.

Other names
couch grass pollen extractquack grass pollen extract

Beyond the preview

Go deeper on elymus repens pollen.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on elymus repens pollen.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call